On Monday, DA Davidson reaffirmed its positive stance on Phreesia Inc . (NYSE: NYSE:PHR) stock, maintaining a Buy rating and a price target of $32.00. The endorsement follows the recent initial public offering (IPO) of Waystar, a peer company in the healthcare technology space, which concluded its first trading day on Friday with shares closing at $20.70.
DA Davidson highlights Phreesia's robust growth trajectory, improved profit margins, lower balance sheet risk, and its current trading price, which is 30% lower than Waystar's, based on next twelve months (NTM) sales multiples. The analyst's valuation of Phreesia at 3.9x sales underscores the firm's confidence in the company's market position relative to its competitors.
Phreesia, which specializes in patient check-in and healthcare payment services, is perceived to have a strong competitive edge in the rapidly evolving healthcare technology sector. The firm's growth and margin expansion have been key factors in securing the confidence of DA Davidson.
The analyst's reiterated price target of $32.00 for Phreesia reflects a significant premium to the company's current trading level. This target is based on the enterprise's sales multiples and represents a bullish outlook for the stock's potential performance.
The reaffirmation of the Buy rating and price target comes at a time when the healthcare technology industry is increasingly in focus, with investors closely watching the performance of companies like Phreesia and Waystar. Phreesia's stock performance and market valuation will continue to be monitored by investors as the company progresses in its financial and operational goals.
In other recent news, healthcare software company Phreesia Inc. has been the subject of multiple analyst reviews following its first-quarter results for fiscal year 2025. JPMorgan (NYSE:JPM) adjusted its price target on Phreesia shares to $27, maintaining an 'Overweight' rating, while RBC (TSX:RY) Capital held steady with a 'Sector Perform' rating and a price target of $23. Needham analysts reiterated their 'Buy' rating with a $29 price target.
Phreesia reported a significant 21% increase in revenue, reaching $101.2 million, and a positive adjusted EBITDA of $4.1 million. The company has updated its FY25 EBITDA outlook, raising it by $7.5 million at the midpoint. Despite these positive financial developments, Phreesia has revised its revenue guidance downward by $8 million due to the hastened conclusion of a clearinghouse partnership.
These are recent developments in the company's pursuit of profitability and growth. Phreesia's recent performance, despite the challenges, demonstrates resilience in its business model. The company's focus on margin improvement and strategic investments are key factors that analysts believe will drive Phreesia's success in the future.
InvestingPro Insights
As Phreesia Inc. (NYSE: PHR) garners positive attention from DA Davidson, real-time data and insights from InvestingPro further inform investors about the company's financial health and market performance. Phreesia's market capitalization stands at $1.12 billion, indicating its size and significance in the healthcare technology sector. Despite a challenging environment for profitability, as reflected in a negative P/E ratio of -9.09, analysts have shown a vote of confidence by revising their earnings upwards for the upcoming period. This suggests that there may be underlying factors that could lead to improved financial results in the future.
While Phreesia does not currently pay a dividend, which might deter income-focused investors, its revenue growth has been notable, with an increase of nearly 24% over the last twelve months as of Q1 2025. This growth trajectory aligns with DA Davidson's positive outlook on the company's market position and potential for margin expansion.
Investors considering Phreesia can also take advantage of additional insights available on InvestingPro, where there are more InvestingPro Tips to guide investment decisions. For those looking to delve deeper into Phreesia's financials and market prospects, using the coupon code PRONEWS24 will secure an extra 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.